From Alphastreet - Earnings Decoded. Market Intelligence Delivered · AlphaStreet Newsdesk · · 40s
Larimar Therapeutics Q3 2026 Results
Larimar Therapeutics reports narrower Q3 2026 loss as it advances rare disease therapies.
In brief
Larimar Therapeutics reports narrower Q3 2026 loss as it advances rare disease therapies. Larimar Therapeutics Inc. posted a $31.1M net loss for Q3 2026, narrowing per-share loss to $0.29 from $0.61 in Q3 2025. Originally reported by Alphastreet - Earnings Decoded. Market Intelligence Delivered.
Q3 2026 Financial Results
Larimar Therapeutics Inc. posted a net loss of $31.1M for Q3 2026.
Per-Share Loss Narrowed
The per-share loss narrowed to $0.29 from $0.61 in Q3 2025, a 52.5% improvement.
Analyst Support

Wall Street maintains a broadly positive view with 8 buy, 1 hold, 0 sell consensus.
In short
Larimar Therapeutics Inc. posted a $31.1M net loss for Q3 2026, narrowing per-share loss to $0.29 from $0.61 in Q3 2025.
Read the TL;DR — this story on one card.





